A Phase II Randomized, Multicenter, Open-Label Trial of Continuing Adjuvant Temozolomide Beyond Six Cycles in Patients With Glioblastoma (GEINO 14-01)
As far as I know this is the first well designed trial to test if 6 or 12 months of Temodar is better. They said 6 months is better. The outcome is the same but the side effects are significantly worse in the 12 month group.
There have been previous reports saying the opposite but they were poorly designed retrospective studies that did not take into account people who stopped at 6 months did so because they weren't doing as well those who chose to continue to 12 months. The current study took people doing well at the end of the 6 months and randomized them so half got 6 additional months and half stopped at 6 months.
Posted on: 04/25/2020
Click HERE to return to brain tumor news headlines